CN1166170A - 新型紫杉化合物、其制备方法及其药物组合物 - Google Patents
新型紫杉化合物、其制备方法及其药物组合物 Download PDFInfo
- Publication number
- CN1166170A CN1166170A CN95195914A CN95195914A CN1166170A CN 1166170 A CN1166170 A CN 1166170A CN 95195914 A CN95195914 A CN 95195914A CN 95195914 A CN95195914 A CN 95195914A CN 1166170 A CN1166170 A CN 1166170A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- atom
- base
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 70
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 33
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 29
- 125000003118 aryl group Chemical group 0.000 claims abstract description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 16
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 12
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 12
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 93
- -1 alkoxy acetic acid Chemical compound 0.000 claims description 69
- 239000002585 base Substances 0.000 claims description 52
- 125000005843 halogen group Chemical group 0.000 claims description 33
- 239000000460 chlorine Substances 0.000 claims description 32
- 125000003368 amide group Chemical group 0.000 claims description 24
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 21
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 125000006239 protecting group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 150000002576 ketones Chemical class 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000005110 aryl thio group Chemical group 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 3
- GBEVOZLAFNMTKL-UHFFFAOYSA-N [O]C(=O)OCC(Cl)(Cl)Cl Chemical compound [O]C(=O)OCC(Cl)(Cl)Cl GBEVOZLAFNMTKL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 3
- MIHIJWOEDDPOLG-DUXPYHPUSA-N (2e)-2-methoxyiminoacetic acid Chemical compound CO\N=C\C(O)=O MIHIJWOEDDPOLG-DUXPYHPUSA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 2
- 150000008045 alkali metal halides Chemical class 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 35
- 241001116500 Taxus Species 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 239000007864 aqueous solution Substances 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 150000001336 alkenes Chemical class 0.000 description 28
- 230000006837 decompression Effects 0.000 description 27
- 150000001721 carbon Chemical group 0.000 description 25
- 229920006395 saturated elastomer Polymers 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 238000005859 coupling reaction Methods 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 239000003960 organic solvent Substances 0.000 description 17
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 229960001866 silicon dioxide Drugs 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- 239000002808 molecular sieve Substances 0.000 description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 238000004237 preparative chromatography Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 150000008065 acid anhydrides Chemical group 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 4
- 125000004953 trihalomethyl group Chemical group 0.000 description 4
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
- GUHWAFYHWQUCJZ-QMTHXVAHSA-N (2r,3s)-2-amino-2-hydroxy-4-[(2-methylpropan-2-yl)oxy]-4-oxo-3-phenylbutanoic acid Chemical compound CC(C)(C)OC(=O)[C@H]([C@@](N)(O)C(O)=O)C1=CC=CC=C1 GUHWAFYHWQUCJZ-QMTHXVAHSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical group CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical class CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 244000162450 Taxus cuspidata Species 0.000 description 2
- 235000009065 Taxus cuspidata Nutrition 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- KQDJZZWCYTXUDE-UHFFFAOYSA-N hydron;thiophene;chloride Chemical compound Cl.C=1C=CSC=1 KQDJZZWCYTXUDE-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 2
- 229960000641 zorubicin Drugs 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- HAKRSIFCTAKBRD-TYFJVFSVSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-1-methoxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@@H]2[C@@]3(C)C(OC)CC(=O)C=C3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C HAKRSIFCTAKBRD-TYFJVFSVSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UHBXGHADNVDXMM-UHFFFAOYSA-N C(C)(C)N(C(C)C)CC[Li] Chemical compound C(C)(C)N(C(C)C)CC[Li] UHBXGHADNVDXMM-UHFFFAOYSA-N 0.000 description 1
- XQCKXOKBWVXUJH-UHFFFAOYSA-N CCOC([O])=O Chemical compound CCOC([O])=O XQCKXOKBWVXUJH-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000208328 Catharanthus Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JOSWYUNQBRPBDN-UHFFFAOYSA-P ammonium dichromate Chemical compound [NH4+].[NH4+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O JOSWYUNQBRPBDN-UHFFFAOYSA-P 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BNSOYWDFFBDEFB-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O BNSOYWDFFBDEFB-UHFFFAOYSA-L 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000025090 microtubule depolymerization Effects 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical group [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 1
- NTJBWZHVSJNKAD-UHFFFAOYSA-N triethylazanium;fluoride Chemical compound [F-].CC[NH+](CC)CC NTJBWZHVSJNKAD-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
新型紫杉化合物(Taxoide),其制备方法及其药物组合物。式中Ra代表氢、羟基、烷氧基、酰氧基、烷氧乙酸基,Rb为氢或Ra与Rb连同与其结合的碳原子共同形成酮官能团;Z代表氢原子或II所示基团,其中R1代表可被取代的苯甲酰基、噻吩甲酰或呋喃甲酰或基团R2-O-CO-,其中R2代表烷基、链烯基、炔基、环烷基、环烯基、二环烷基、可被取代的苯基或杂环基,R3为烷基、链烯基、炔基、环烷基、苯基、萘基或芳香杂环基。R4代表烷基、链烯基、炔基、环烷基、环烯基、二环烷基、芳基或杂环基,R5为烷基、链烯基、炔基、环烷基或可被取代的环烯基。其中Z为式II所示基团的新化合物I具有显著的抗肿瘤和抗白血病特性。
Description
本发明涉及新型紫杉化合物(taxoide)(I)式中:Ra代表氢原子或羟基、C1-4烷氧基、C1-4酰氧基或其烷基部分含1-4个碳原子的烷氧基乙酸基,Rb代表氢原子或者Ra与Rb连同与其结合的碳原子共同形成酮官能团,Z代表氢原子或基团(II):式中:R1代表可被一个或多个相同或不同选自卤原子和C1-4烷基、C1-4烷氧基或三氟甲基的原子或基团取代的苯甲酰基,噻吩甲酰或糠酰,或基团R2-O-CO-,其中R2代表:-C1-8烷基、C2-8链烯基、C3-8炔基、C3-6环烷基、C4-6环烯基、C7-10二环烷基,这些基团可以被一个或多个选自下列取代基的基团取代:卤原子和羟基、C1-4烷氧基、其中每一烷基部分均含1-4个碳原子的二烷基胺基、哌啶子基、吗啉代、哌嗪-1-基(在4-位可以被C1-4烷基或其中烷基部分含1-4个碳原子的苯基烷基取代)、C3-6环烷基、C4-6环烯基、苯基(可以被一个或多个选自卤原子和C1-4烷基或C1-4烷氧基的原子或基团取代)、氰基、羧基或其中烷基部分含1-4个碳原子的烷氧羰基,-可以被一个或多个选自下列原子或基团的取代基取代的苯基或α-或β-萘基:卤原子和C1-4烷基或C1-4烷氧基或优选自呋喃基与噻吩基的5员芳族杂环基,-或可被一个或多个C1-4烷基取代的C4-6饱和杂环基,R3代表直链或支链C1-8烷基,直链或支链C2-8链烯基,直链或支链C2-8炔基,C3-6环烷基,可被一个或多个选自下列原子或基团的取代基取代的苯基或α-或β-萘基:卤原子、烷基、链烯基、炔基、芳基、芳烷基、烷氧基、烷硫基、芳氧基、芳硫基、羟基、羟烷基、巯基、甲酰基、酰基、酰氨基、芳酰氨基、烷氧羰基氨基、氨基、烷基氨基、二烷基氨基、羧基、烷氧羰基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、氰基、硝基与三氟甲基,或含一个或多个选自氮、氧或硫的相同或不同杂原子的可被一个或多个相同或不同选自下列基团的取代基取代的5员芳族杂环:卤原子和烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧羰基氨基、酰基、芳基羰基、氰基、羧基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰或烷氧羰基,条件是在苯基、α-或β-萘基与芳族杂环基的取代基中,烷基与其它基团的烷基部分均含1-4个碳原子并且链烯基与炔基含2-8个碳原子以及芳基为苯基或α-或β-萘基,R4代表-直链或支链C1-8烷基,直链或支链C2-8链烯基,直链或支链C2-8炔基,C3-6环烷基,C4-6环烯基或C7-11二环烷基,这些基团可以被一个或多个选自下列取代基的基团取代:卤原子和羟基、C1-4烷氧基、其中每一个烷基部分含1-4个碳原子的二烷基氨基、哌啶子基、吗啉代、哌嗪-1-基(在4-位可被C1-4烷基或其烷基部分含1-4个碳原子的苯基烷基取代)、C3-6环烷基、C4-6环烯基、可被取代的苯基、氰基、羧基或其烷基部分含1-4个碳原子的烷氧羰基,-或者可被一个或多个选自下列原子或基团的取代基取代的芳基:卤原子和烷基、链烯基、炔基、芳基、芳烷基、烷氧基、烷硫基、芳氧基、芳硫基、羟基、羟烷基、巯基、甲酰基、酰基、酰氨基、芳酰氨基、烷氧羰基氨基、氨基、烷基氨基、二烷基氨基、羧基、烷氧羰基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、氰基、硝基、叠氮基、三氟甲基或三氟甲氧基,或可被一个或多个C1-4烷基取代的4-6员饱和或不饱和杂环基,R5代表-直链或支链C1-8烷基,直链或支链C2-8链烯基,直链或支链C2-8炔基,C3-6环烷基,C4-6环烯基或C7-11二环烷基,这些基团可以被一个或多个选自下列取代基的基团取代:卤原子和羟基、C1-4烷氧基、其中每一个烷基部分含1-4碳原子的二烷基氨基、哌啶子基、吗啉代、哌嗪-1-基(在4-位可被C1-4烷基或其烷基部分含1-4个碳原子的苯基烷基取代)、C3-6环烷基、C4-6环烯基、可被取代的苯基、氰基、羧基或其烷基部分含1-4个碳原子的烷氧羰基,条件是环烷基、环烯基或二环烷基可以被一个或多个C1-4烷基取代。
优选地,可以被R3和/或R4表示的芳基为可以被一个或多个选自下列原子或基团的取代基取代的苯基或α-或β-萘基:卤原子(氟、氟、溴、碘)和烷基、链烯基、炔基、芳基、芳烷基、烷氧基、烷硫基、芳氧基、芳硫基、羟基、羟烷基、巯基、甲酰基、酰基、酰氨基、芳酰氨基、烷氧羰基氨基、氨基、烷基氨基、二烷基氨基、羧基、烷氧羰基、氨基甲酰基、二烷基氨基甲酰基、氰基、硝基、叠氮基、三氟甲基和三氟甲氧基,条件是烷基与其它基团中的烷基含1-4个碳原子、链烯基与炔基含2-8个碳原子和芳基为苯基或α-或β-萘基。
优选地,可以用R3和/或R4表示的杂环基为含有一个或多个相同或不同选自氮、氧或硫的原子被选自下列一个或多个相同或不同取代基取代的5员芳族杂环基:卤原子(氟、氯、溴、碘)和C1-4烷基、C6-10芳基、C1-4烷氧基、C6-10芳氧基、氨基、C1-4烷基氨基、其中烷基部分含1-4个碳原子的二烷基氨基、其中酰基部分含1-4个碳原子的酰基氨基、C1-4烷氧羰基氨基、C1-4酰基、其中芳基部分含6-10个碳原子的芳基羰基、氰基、羧基、氨基甲酰基,其中烷基部分含1-4个碳原子的烷基氨基甲酰基、其中每一烷基部分均含有1-4个碳原子的二烷基氨基甲酰基或其烷氧基部分含1-4个碳原子的烷氧羰基。
更具体地,本发明涉及通式I所示化合物,其中Ra代表羟基、C1-4烷氧基、C1-4酰氧基或其中烷基部分含1-4个碳原子的烷氧基乙酸基,Rb代表氢原子;Z代表氢原子或通式II所示基团,其中R1代表苯甲酰基或其中R2代表叔丁基的基团R2-O-CO-,R3代表C1-6烷基、C2-6链烯基、C3-6环烷基、可被一个或多个相同或不同选自下列原子或基团的取代基取代的苯基:卤原子(氟、氯)和烷基(甲基)、烷氧基(甲氧基)、二烷基氨基(二甲氨基)、酰氨基(乙酰氨基)、烷氧羰基氨基(叔丁氧羰基氨基)或三氟甲基或呋喃-2-基或呋喃-3-基、噻吩-2或-3-基或噻唑-2,-4或-5-基,R4代表可被一个或多个相同或不同选自下列原子或基团的取代基取代的苯基:卤原子和烷基、烷氧基、氨基、烷基氨基、二烷基氨基、酰基氨基、烷氧羰基氨基、叠氮基、三氟甲基和三氟甲氧基,或噻吩-2或-3-基或呋喃-2或-3-基,R5代表可被取代的C1-4烷基。
进一步更为具体地,本发明涉及通式(I)所示的化合物,其中Ra代表氢原子或羟基或乙酸基或甲氧乙酸基,Rb代表氢原子,Z代表氢原子或通式(II)所示基团,其中R1代表苯甲酰基或其中R2代表叔丁基的基团R2-O-CO-,R3代表异丁基、异丁烯基、丁烯基、环己基、苯基、呋喃-2-基、呋喃-3-基、噻吩-2-基、噻吩-3-基、噻唑-2-基、噻唑-4-基或噻唑-5-基,R4代表可被一个卤原子取代的苯基,R5代表C1-4烷基。
其中Z代表通式(II)所示基团的通式I所示化合物具有显著的抗肿瘤和抗白血病特性。
按照本发明,其中Ra代表氢原子或烷氧基、酰氧基或烷氧乙酸基,Rb代表氢原子,R4、R5与Z如上定义的化合物I可以通过碱金属卤化物(NaCl、NaI、KF)或碱金属叠氮化物(叠氮化钠)或季铵盐或碱金属的磷酸盐对通式(III)所示化合物产生作用、以便得到通式(V)所示的化合物,随后如果需要用氢原子替代Ra或R7和/或R6与R7表示的保护基来制备:式中Z1代表氢原子或式II所示其中R1与R3如上定义的基团或下式所示基团式中R1与R3如上限定,或R6代表氢原子,R7代表羟基官有团的保护基,或R6与R7共同形成5或6员饱和杂环,式R4、R5如上限定,Ra代表氢原子或烷氧基、酰氧基、烷氧乙酸基或被保护羟基,优选2,2,2-三氯乙氧羰基氧,Rb代表氢原子,或Ra与Rb以及与它们连结的碳原子共同形成酮官能团,式中Z1、R4、R5、Ra与Rb如上限定。
一般地,该反应在选自醚(四氢呋喃、二异丙醚、甲基叔丁基醚)与纯腈(乙腈)或其混合物的有机溶剂中在20℃至反应混合物的沸点范围内进行。
式中Z1代表氢原子或通式II所示基团、Ra代表氢原子或羟基、C1-4烷氧基、C1-4酰氧基或其中烷基部分含1-4个碳原子的烷氧乙酸基而Rb代表氢原子或Ra与Rb以及与它们连结的碳碳原子共同形成酮官能团的通式(V)所示化合物与化合物I相同。
在通式V中,当Z代表通式(IV)所示基团和R6代表氢原子时,R7优选为甲氧甲基、1-乙氧乙基、苄氧甲基、三甲基甲硅烷基、三乙基甲硅烷基、β-三甲基甲硅烷基乙氧基甲基、苄氧羰基或四氢吡喃基。当R6与R7共同形成杂环时,它优选为可在2位被单取代或偕二取代的噁唑烷环。
用氢原子替代保护基R7和/或R6和R7以及可能地用羟基置换Ra的过程可以根据其特性以下列方式进行:1)当R6代表氢原子,R7代表羟基官能团的保护基,Ra代表烷氧基、酰氧基或烷氧乙酸基时,氢原子置换保护基的过程借助以纯态或混合物形式存在的无机酸(盐酸、硫酸、氢氟酸)或有机酸(乙酸、甲磺酸、三氟甲磺酸、对甲苯磺酸)在选自醇、醚、酯、脂肪烃、卤代脂肪烃、芳烃或腈的有机溶剂中在-10~60℃下进行,2)当R6代表氢原子,R7代表羟基官能团保护基,Ra代表2,2,2-三氯乙氧羰基氧时,保护基R7的置换过程在1)所述条件下进行,Ra的置换过程通过用锌与视需要而存在的铜相结合进行处理,在30-60℃乙酸存在下或借助无机或有机酸如盐酸或乙酸与C1-3脂肪醇(甲醇、乙醇、丙醇、异丙醇)或脂族酯(乙酸乙酯、乙酸异丙酯、乙酸正丁酯)形成的溶液在可以与铜结合的锌存在下进行,3)当R6与R7共同形成5或6员饱和杂环以及更具体地通式(VI)所示噁唑烷环时,式中R1如上限定,R8与R9相同或不同,代表氢原子或C1-4烷基,或其中烷基含1-4个碳原子、芳基部分优选为可被一个或多个C1-4烷氧基取代的苯基的芳烷基,或优选为可被一个或多个C1-4烷氧基取代的苯基的芳基,或R8为C1-4烷氧基或三卤代甲基如三氯甲基或可被三卤代甲基如三氯甲基取代的苯基,R9为氢原子,或R8与R9连同与其结合的碳原子共同形成4-7员环,Ra为酰氧基或烷氧乙酸基或2,2,2-三氯乙氧羰基氧,用氢原子置换由R6与R7形成的保护基以及用羟基置换Ra的过程可以根据Ra、R1、R8和R9的定义以下列方式进行:a)当R1为叔丁氧羰基,R8与R9相同或不同,代表烷基或芳烷基(苄基)或芳基(苯基),或R8代表三卤代甲基或被三卤代甲基取代的苯基,R9代表氢原子,或R8与R9共同形成4-7员环时,用无机或有机酸视需要而定在有机溶剂如醇对通式(V)所示酯进行处理,得到下式所示产物:式中Ra、Rb、R3、R4和R5如上定义,该化合物借助其中苯核可被取代的苯甲酰氯、噻吩甲酰氯、呋喃甲酰氯或通式(VIII)所示化合物酰化
R2-O-CO-X (VIII)式中R2如上定义,X代表卤原子(氟,氯)或残基-O-R2或-O-CO-OR2,得到通式(IX)所示化合物式中Ra、Rb、R1、R3、R4和R5如上所限定,其中保护基Ra在代表被保护羟基时在必要条件下被羟基取代。
优选地,通式(V)所示产物在约20℃下经过甲酸处理。
优选地,借助其中苯基可被取代的苯甲酰氯、噻吩甲酰氯或呋喃甲酰氯或通式(VIII)所示化合物对化合物(IX)进行酰化的过程在选自酯如乙酸乙酯、乙酸异丙酯或乙酸正丁酯和卤代脂族烃如二氯甲烷或1,2-二氯乙烷的惰性有机溶剂中在无机碱如碳酸氢钠或有机碱如三乙胺存在下进行。反应温度为0-50℃,以约20℃为佳。
优选地,在Ra代表2,2,2-三氯乙氧基羰基氧时,Ra的保护基的置换过程在上面2)所述条件下进行。b)当R1代表可被取代的苯甲酰基、噻吩甲酰基或呋喃甲酰基或其中R2如上限定的基团R2O-CO-,R8代表氢原子或C1-4烷氧基或可被一个或多个C1-4烷氧基取代的苯基、 R9代表氢原子时,用氢原子置换由R6和R7形成的保护基的过程在以纯态或混合物形式存在的无机酸(盐酸、硫酸)或有机酸(乙酸、甲磺酸、三氟甲磺酸、对甲苯磺酸)以化学计量或催化量存在下在选自醇、醚、酯、脂族烃、卤代脂族烃和芳烃的有机溶剂中在-10~60℃、优选在15-30℃进行,而在Ra代表2,2,2-三氯乙氧羰基氧时Ra的保护基被氢原子置换的过程在上面2)所述条件下进行。4)当Ra为烷氧乙酸基和R6与R7如上述1)所限定时,首先通过在上述1)所述酸性条件下进行操作来用氢原子置换保护基R7,随后视需要而定通过在碱性介质中进行处理或在不触及分子其它部分的条件下通过卤化锌的作用借助羟基置换Ra,一般地,通过在稀酒精介质中的氨或者通过在稀酒精介质中的水合肼作用下于约20℃进行碱性处理。一般地,借助卤化锌、优选地碘化锌进行的处理过程可在约20℃下的甲醇中进行。5)当Ra为烷氧乙酸基,R6与R7如上述3-a)所定义时,通过在碱性介质中进行处理或通过卤化锌在上述4)的条件下进行处理进行用羟基置换Ra基团的过程,随后处理在上述3-a)的去保护和酰化条件下得到的化合物(V)。6)当Ra代表烷氧乙酸基,R6与R7如上面3-b)所述时,用羟基置换Ra的过程通过在上面4)所述条件下在碱性介质中进行处理或通过用卤化锌进行处理来进行,随后处理在上面3-b)所述条件下所得到的产物。
其中Z1代表通式(II)或(IV)所示基团的通式(III)所示化合物可以通过借助通式(XI)所示酸或该酸衍生物将通式X所示化合物酯化成为通式(XII)所示酯、随后根据需要用氢原子替代用R7和/或R6和R7代表的保护基以及可能的在Ra代表酰氧基、烷氧乙酸基或被保护羟基时在上述替代其中Z1代表通式(IV)所示基团的通式(V)所示化合物中保护基的条件下用羟基去除Ra保护基来获得:
式中R1与R3如上限定,或R6代表氢原子,R7代表羟基官能团保护基,或R7与R6共同形成5或6员饱和杂环式中Ra、Rb、R1、R3、R4、R5、R6和R7如上所述。
借助通式(XI)所示酸进行的酯化反应可在缩合剂(碳化二亚胺、活性碳酸盐)和活化剂(氨基吡啶)存在下在有机溶剂(醚、酯、酮、腈、脂肪烃、卤代脂肪烃、芳烃)中于-10~90℃下完成。
该酯化反应还可以采用以酐形式存在的通式XI所示酸在活化剂(氨基吡啶)存在下在有机溶剂(醚、酯、酮、腈、脂肪烃、卤代脂肪烃、芳烃)中于0-90℃下进行。
该酯化反应还可以采用以卤化物或酐形式存在的通式XI所示酸和可即时制备的脂族酸或芳族酸在碱(脂族叔胺)存在下在有机溶剂(醚、酯、酮、腈、脂族烃、卤代脂族烃、芳烃)中于0-80℃下进行。
按照本发明,其中R4与R5如上限定,Ra代表氢原子或烷氧基、酰氧基或烷氧乙酸基、Rb代表氢原子并且Z1代表氢原子的通式(III)所示化合物可以通过三氟甲磺酸的衍生物如该酸的酐或N-苯基三氟甲磺酰亚胺对通式(XIII)所示化合物的作用而得到:式中Ra、Rb、R4与R5如上限定。
一般地,该反应在惰性有机溶剂(可被卤代的脂肪烃、芳烃)中于有机碱如脂族叔胺(三乙胺)或吡啶存在下在-50~20℃下进行。
其中R4与R5如上限定、Ra为氢原子或烷氧基、酰氧基或烷氧乙酸基或被保护羟基、Rb为氢原子的通式(XIII)所示化合物可以通过氢氟酸或三氟乙酸在碱性有机溶剂如可被一个或多个C1-4烷基取代的吡啶或可与惰性有机溶剂如CH2Cl2或乙腈或四氢呋喃缔合的三乙胺之中于20-80℃下与化合物(XIV)相互作用来获得:式中R4与R5如上限定,Ra代表氢原子或烷氧基、酰氧基或烷氧乙酸基或被保护羟基,Rb代表氢原子,G1为三烷基甲硅烷基。
其中Ra为烷氧基、酰氧基或烷氧乙酸基或被保护羟基而Rb为氢原子的化合物(XIV)可以通过化合物(XV)R-Y(其中R为烷基、链烷酰基或烷氧乙酰基或羟基官能团的保护基,Y为卤原子)与其中R4、R5与G1如上限定的化合物(XVI)相互作用来获得。
当R为链烷酰基或烷氧乙酰基时,特别有利的是在碱性有机溶剂如吡啶或在惰性有机溶剂如CH2Cl2、氯仿或1,2-二氯乙烷中在叔胺如三乙胺或吡啶存在下于约0℃进行操作。
当R为烷基时,特别有利的是借助碱金属氢化物(NaH)或金属烷基化物(丁基锂)在2位上对羟基官能团预先进行金属化处理。
化合物(XVI)以及在可能情况下化合物(XIV)可以通过其中R4如上限定以及M为金属原子、优选为锂或镁的有机金属衍生物R4-M(XVII),与其中Ra、Rb、R5和G1如上限定的化合物(XVIII)相互作用来制备
一般地,该反应在有机溶剂如醚(四氢呋喃)中于-50℃以下、优选约-78℃的温度下进行。
特别有利的作法是借助预先经过通式XX所示化合物处理的碱金属氢化物或氨基化物如氢化钠或二异丙基氨基化锂的作用将通式(XIX)所示化合物的叔羟基官能团金属化。
一般情况下,该反应在极性有机溶剂如二甲基甲酰胺中在0-50℃下进行。
化合物(XIX)可以通过化合物(XV)与其中G1如上限定的化合物(XXI)在上述化合物(XV)与化合物(XVI)相互作用的条件下进行反应来制备。
化合物(XXII)可以通过卤代三烷基硅烷与其中G1如上限定的化合物(XXIII)在碱性有机溶剂中相互作用得到。
可以在D.G.I.Kingston等人,Journal of Nat.Prod.56,884(1993)所述条件下制备化合物(XXIII)。
其中R4为苯基、R5如上定义,Ra为氢原子或羟基、烷氧基、酰氧基或烷氧乙酸基或被保护羟基而Rb为氢原子的通式(XIV)所示化合物可以通过通式XX所示化合物与下式所示化合物在上述化合物XX与XIX反应的条件下相互作用来获得式中Ra、Rb和G1如上所述。
该反应优选地在有机溶剂如二甲基甲酰胺中在咪唑存在下进行。
式中Ra为烷氧基、酰氧基或烷氧乙酸基而Rb为氢原子、G1如上定义的通式(XXIV)所示化合物可以通过通式(XV)所示化合物与通式(XXVI)所示化合物在化合物XV与XVI如上所述相互作用的条件下进行反应来制备。式中G1如上定义。
化合物XXVI可以通过卤代三烷基硅烷与化合物XXV在上述卤代三烷基硅烷与化合物XXII反应条件下相互作用而获得。
通式(XXV)所示产物可以在D.G.I.Kingston等人Tetraheclron Letters35,6839(1992)所述条件下获得。
其中Ra与Rb分别为氢原子的化合物I可以通过电解还原其中Ra为羟基或酰氧基或烷氧乙酸基的化合物I或者在国际申请PCTWO 93/06093中所述条件下获得。
其中Ra与Rb连同与其结合的碳原子共同形成酮官能团的化合物I可以通过其中Ra为羟基、Rb为氢原子的化合物I借助,例如氯铬酸吡啶鎓、重铬酸吡啶鎓、重铬酸钾、重铬酸铵或二氧化锰被氧化而获得。
可以按照诸如结晶或色谱法之类已知方法提纯通过实施本发明方法得到的新型化合物I。
其中Z为通式II所示基团的化合物I具备重要的生物特性。
可以借助M.L.Shelanski等人的Proc.Natl.Acad.Sci.USA,70,765-768(1973)所述方法在体外对猪脑微管蛋白提取物进行生物活性测定。对将微管解聚为微管蛋白的研究按照G.Chauviere等人的C.R.Acad.Sci.293,系列II 501-503(1981)所述方法进行。其中Z为通式II所示基团的化合物I至少表现出与紫杉酚和taxotere相同的活性。
在活体内进行的试验中,其中Z为通式II所示基团的化合物I在被植入黑素瘤B16的小鼠体内以1-10mg/kg的剂量通过腹膜内给药表现出活性,它对其它液体或固体肿瘤也具有疗效。
这些新型化合物具备抗肿瘤特性,更具体地讲对那些对Taxol或Taxotere已产生抗药性的肿瘤具有拮抗活性。这类肿瘤包括具有基因mdrl(多重抗药性基因)的高表达的结肠肿瘤。多重抗药性是一个常用术语,意味着肿瘤对结构与作用机理不同的化合物的抗药性。紫杉化合物通常由于实验肿瘤如P388/DOX(一种由于对表示为mdr1的阿霉素(DOX)的抗药性而被选中的细胞系)而被广泛了解。
下列实施例用于描述本发明。
实施例1
将40mg 3-叔丁氧羰基-2-(4-甲氧基苯基)-4-苯基-1,3-噁唑烷-(2R,4,5R)-5-羧酸2α-苯甲酸基-1β,10β-二羟基-5β,20-环氧基-4α-甲氧基-7β,8-亚甲基-19-降-9-氧-11-紫杉烯(Taxene)-13α-酯与450μl 0.1N乙醇盐酸溶液形成的溶液在约0℃下搅拌约3小时。在20℃减压(2.7KPa)浓缩至干。将反应粗产物溶于10cm3 CH2Cl2和10cm3 NaHCO3饱和水溶液。倾析分离有机相,用10cm3 NaCl饱和水溶液洗涤2次。用MgSO4干燥。过滤并且在40℃减压(2.7Kpa)浓缩至干。得到59g产物,在0.5mm厚的硅胶板上进行制备色谱提纯(洗提剂:环己烷/乙酸乙酯60/40体积)。因此得到12mg白色烤蛋白状(2R,3S)3-叔丁氧羰基氨基-2-羟基-3-苯基(2R,3S)丙酸2α-苯甲酰氧-1β,10β-二羟基-5β,20-环氧,-4α-甲氧-7β,8-亚甲基-19-降-9-氧-11-紫杉烯-13α-酯,其物理特征如下所示:-质子核磁共振谱(400 MHz;CDCl3;δppm;偶合常数J Hz):1,20(s,6H:CH3);1,35(s,9H:C(CH3)3;1,35~1,60(mt,1H:H7);1,73(s,1H:OH 1);1,81和2,27(2mts,1H单峰:CH2 19);1,90(s,3H:CH3);2,07和2,26(2mts,1H单峰:CH2 6);2,35和2,87(2mts,1H单峰:CH2 14);3,24(mt,1H:OH 2′);3,46(s,3H:OCH3);3,70(d,J=7,1H:H 3);3,97和4,39(2 d,J=9,1H单峰:CH2 20);4,24(s宽,1H:OH 10);4,62(mt,1H:H 2′);4,90(d宽,J=4,1H:H 5);4,98(s,1H:H 10);5,36(mt,1H:H 3′);5,48(d,J=10,1H:CONH);5,69(d,J=7,1H:H 2);6,24(mt,1H:H 13);7,25~7,50(mt,5H:H 芳香3′);7,49(t,J=7,5,2H:OCOC6H5H间位;7,57(t,J=7,5,1H:OCOC6H5H对位);8,12(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸2α-苯甲酰氧-1β,10β-二羟基-5β,20-环氧-4α-甲氧基-7β,8-亚甲基-19-降-9-氧-11-紫杉烯-13α-酯:
向112mg 3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸2α-苯甲酸基-5β,20-环氧-1β10β-二羟基-9-氧-4α-甲氧-7β-三氟甲磺酰氧-11-紫杉烯(Taxene)-13α-酯与1cm3乙腈和0.1cm3四氢呋喃的溶液中依次加入100mg粉状4A分子筛、100mg迭氮化钠。在约75℃将反应介质搅拌3小时,随后在约20℃,加入50cm3 CH2Cl2和50cm3NaCl饱和水溶液。倾析有机相,用NaCl饱和水溶液40cm3洗涤2次,随后用MgSO4干燥、过滤并在40℃减压(2.7Kpa)浓缩至干。得到77mg产物,用2mm厚的硅胶板进行制备色谱提纯(洗提剂:CH2Cl2/CH3OH:90/10体积),得到45mg3白色烤蛋白状目的产物,其特征如下所示:-质子核磁共振谱(400MHz;CDCl3;330°K;δppm;偶合常数J Hz):1,10(s,9H:C(CH3)3);1,20(s,3H:CH3);1,22(s,3H:CH3);1,29(mt,1H:H en 7);1,68(s,3H:CH3);1,78和 2,252,35(2mts,1H单峰:CH2 19);1,99和2,24(dt和d宽,J=17和4和J=17,1H单峰:CH2 6);2,25~2,35和2,56(mtdd(J=15和7),1H单峰:CH2 14);3,06(s,3H:OCH3);3,67(d,J=7,1H:H 3);3,80(s,3H:ArOCH3);3,96和4,26(2 d,J=9,1H单峰:CH220);4,17(s宽1H:OH 10);4,66(d,J=5,1H:H 2′);4,78(d宽,J=4,1H:H 5);4,92(s宽1H:H 10);5,48(mt,1H:H 3′);5,66(d,J=7,1H:H 2);6,05(mt,1H:H 13);6,38(s,1H:H 5′);6,91(d,J=8,5,2H:H芳香邻位OCH3);7,30~7,50(mt,7H:H芳香3′和OCOC6H5H间位 ;7,41(d,J=8,5,2H:H芳香间位OCH3);7,58(t,J=7,5,1H:OCOC6H5H对位);7,96(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸2α-苯甲酰氧-5β,20-环氧-1β,10β-二羟基-9-氧-4α-甲氧基-7β-三氟甲磺酰氧-11-紫杉烯-13α-酯:
在约20℃,向由100mg 2α-苯甲酰氧-1β,10β,13α-三羟基-5β,20-环氧-9-氧-4α-甲氧基-7β-三氟甲磺酰氧-11-紫杉烯在4cm3无水乙酸乙酯中形成的溶液中依次加入70mg 3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸、50mg二环己基碳化二亚胺和6mg 4-二甲氨基吡啶。在氩气氛中在约20℃将反应混合物搅拌3.3小时,加入30cm3乙酸乙酯和20cm3饱和NH4Cl水溶液。倾析分离有机相,用20cm3水洗二次,用MgSO4干燥。过滤并在40℃减压(2.7KPa)浓缩至干。得到的200g产物在15g硅胶(0.063-0.2mm)柱(直径为1cm)中进行色谱提纯(洗提剂,环己烷/乙酸乙酯80-20体积),得到8cm3馏份。合并仅含目的化合物的馏份并且在40℃减压(2.7KPa)浓缩至干,得112mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(400MHz;CDCl3,333°K,δppm;偶合常数J Hz):1,10(s,9H:C(CH3)3);1,13(s,3H:CH3);1,18(s,3H:CH3);1,77(s,3H:CH3);1,87(s,3H:CH3);2,33和2,76(2 dd,J=15和11Hz和J=15和7,1H单峰:CHx 14);2,36和2,68(2mts,1H单峰:CH2 6);3,19(s,3H:OCH3);3,44(d,J=6,1H:H 3);3,83(s,3H:ArOCH3);3,95(s宽1H:OH 10);4,19和4,34(2d,J=9,1H单峰:CH2
20);4,66(d,J=5,5,1H:H 2′);4,85 4,95(mt,2H:H 7和H 5);5,32(s宽1H:H 10);5,49(d,J=5,5,1H:H 3′);5,60(d,J=6,1H:H2);5,95(mt,1H:H 13);6,38(s,1H:H en 5′);6,94(d,J=8,5,2H:H
芳香邻位OCH3);7,30~7,50(mt,7H:H芳香3′和OCOC6H5H间位);7,40(d,J=8,5,2H:H芳香间位OCH3);7,60(t,J=7,5,1H:OCOC6H5H对位;7,97(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备2α-苯甲酸基-5β,20-环氧-4α-甲氧基-9-氧-7β-三氟甲磺酰氧基-1β,10β,13α-三羟基-11-紫杉烯:
向51.6mg 2α-苯甲酰氧-5β,20-环氧-9-氧-4α-甲氧基-1β,7β,10β,13α-四羟基-11-紫杉烯于0.5cm3CH2Cl2和24μl吡啶中形成的约0℃的溶液中加25μl三氟甲磺酸酐。在约0℃将反应混合物搅拌20分钟,随后加入3cm3水和15cm3CH2Cl2。倾析有机相,用10cm3NH4Cl饱和水溶液洗涤2次,随后用MgSO4干燥,过滤并在20℃减压(2.7KPa)浓缩至干。得到的72mg产物用2mm厚硅胶板进行色谱提纯(洗提液,CH2Cl2-甲醇:90-10体积),得到8mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(400MHz;CDCl3;δppm;偶合常数J Hz):1,06(s,3H:CH3);1,10(s,3H:CH3);1,86(s,3H:CH3);2,13(s,3H:CH3);2,41和2,74(2mts,1H单峰:CH2 6);2,47和2,59(2 dd,J=16和10和J=16和4,1H单峰:CH2 14);2,96(d宽,J=10,1H:OH 13);3,66(s,3H:OCH3);3,79(d,J=6,1H:H 3);3,95(s宽,1H:OH 10);4,30和4,49(2d,J=9,1H单峰:CH2 20);4,57(mt,1H:H 13);4,98(dd,J=12和6,1H:H 7);5,04(dd,J=10和3,1H:H 5);5,42(s宽,1H:H 10);5,61(d,J=6,1H:H 2);7,59(t,J=7,5,2H:OCOC6H5H间位);7,63(t,J=7,5,1H:OCOC6H5H对位);8,00(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备2α-苯甲酸基-5β,20-环氧-4α-甲氧基-9-氧-1β,7β,10β,13α-四羟基-11-紫杉烯:
向338mg 2α-苯甲酰氧-1β,10β-二羟基-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-4α-甲氧基-11-紫杉烯于5cm3CH2Cl中形成的溶液中于约20℃加入7.5cm3三乙胺一氢氟酸配合物。在约20℃将反应混合物搅拌2小时,随后加入50cm3CH2Cl2和50cm3 NaHCO3饱和水溶液。倾析有机相,用50cm3NaCl饱和水溶液洗涤2次,随后用MgSO4干燥,过滤并在40℃下减压(2.7KPa)浓缩至干。得到的420mg产物在60g硅胶(0.063-0.2mm)柱(直径:1cm)中进行色谱提纯(洗提剂:CH2Cl2-MeOH 95-5,体积),得到馏分10cm3。合并仅含目的化合物的馏分并在40℃减压(2.7KPa)浓缩至干。得到184g白色烤蛋白状目的化合物,其物理特征在于:
-质子核磁共振谱(400MHz;CDCl3;δenppm;偶合常数
J Hz):1,05(s,3H:CH3);1,10(s,3H:CH3);1,72(s,3H:CH3);1,99和
2,40~2,55(2mts,1H单峰:CH2 6);2,09(s,3H:CH3);2,48和2,69(2 dd,
J=16和10和J=16和4,1H单峰:CH2 14);3,15(d 宽,J=11,1H:OH 13);3,65 (s,3H:OCH3);3,74(d,J=6,1H:H en 3);3,78(dd,J=12和6,1H:H7);4,13(s宽,1H:OH 10);4,31和4,45(2d,J=9,5,1H单峰:CH220);4,54(mt,1H:H en 13);5,00(dd,J=10和3,1H:H 5);5,27(s宽,1H:H 10);5,61(d,J=6,1H:H 2);7,48(t,J=7,5,2H:OCOC6H5H间位);7,62(t,J=7,5,1H:OCOC6H5H对位;8,03(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备2α-苯甲酰氧-1β,10β-二羟基-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-4α-甲氧基-11-紫杉烯:
向940mg 1β,2α-碳酸酯-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-10β-甲氧乙酸基-9-氧-4α-甲氧基-11-紫杉烯于45cm3无水四氢呋喃中形成的溶液中加入2.22cm3 1M苯基锂于四氢呋喃中形成的约-78℃溶液。在约-78℃搅拌该反应混合物2小时30分钟,随后加入20cm3NH4Cl饱和水溶液。在约20℃,加入50cm3水和100cm3乙酸乙酯。倾析有机相,用50cm3NaCl饱和水溶液液洗涤2次,用MgSO4干燥,过滤,在40℃减压(2.7KPa)浓缩至干。得到的1.2g产物在直径为3cm的100g硅胶(0.063-0.2mm)柱上进行色谱提纯(洗提液:乙酸乙酯-环己烷:15-85,体积),得到10cm3馏分,合并仅含目的产物的馏分,于40℃减压(2.7KPa)浓缩至干,得到734mg白色烤蛋白状目的化合物,其物理特征在于:
质子核磁共振谱(400MHz;CDCl3,δppm;偶合常数J
Hz):0,55(mt,6H:CH2乙基);0,70(q,J=7,5,6H:CH2乙基);0,93(t,J=7,5,9H:CH3乙基);1,05(t,J=7,5,9H:CH3乙基);1,09(s,3H:CH3);1,14(s,3H:CH3);1,55(s,1H:OH 1);1,71(s,3H:CH3);2,02和2,33(2mts,1H单峰:CH2 6);2,07(s,3H:CH3);2,12和2,74(2dd,J=15和9Hz和J=15和7,5,1H单峰:CH2 14);3,43(s,3H:OCH3);3,47(d,J=7,1H:H 3);3,85(dd,J=11和6,1H:H 7);4,17和4,29(2 d,J=8,5,1H单峰:CH2 20);4,27(d,J=2,1H:OH 10);4,95(mt,1H:H 13);5,00(dd,J=10和3,1H:H5);5,14(d,J=2,1H:H 10);5,59(d,J=7,1H:H 2);7,45(t,J=7,5,2H:OCOC6H5H间位;7,57(t,J=7,5,1H:OCOC6H5H对位);8,07(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备1β,2α-碳酸酯-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-10β-甲氧乙酸基-9-氧-4α-甲氧基-11-紫杉烯:
在约20℃和氩气氛下向510mg 1β,2α-碳酸酯-7β,13α-二(三乙基甲硅烷氧)-5β,20-环氧-4α-羟基-10β-甲氧乙酸基-9-氧-11-紫杉烯在6cm3二甲基甲酰胺中形成的溶液中加0.3g4A分子筛、12cm3甲基碘和90mg氢化钠。在约20℃下搅拌3小时。加入10cm3NH4Cl饱和水溶液和30cm3CH2Cl2。倾析分离有机相。用10cm3NaCl饱和水溶液洗涤2次,随后用MgSO4干燥。过滤,在40℃减压(2.7KPa)浓缩至干。得到715mg产物,在50g硅胶(0.063-0.2mm)柱(直径:1cm)中进行色谱提纯(洗提液:乙酸乙酯-环己烷:25-75,体积)得到馏份10cm3,合并仅含目的产物的馏分并在40℃减压(2.7KPa)浓缩至干,得到494mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(400MHz;CDCl3;δppm;偶合常数J Hz):0,60(q,J=7,5,6H:CH2乙基);0,68(q,J=7,5,6 H:CH2乙基;0,92(t,J=7,5,9H:CH3 乙基);1,03(t,J=7,5,9H:CH3 乙基);1,19(s,3H:CH3);1,23(s,3H:CH3);1,44(s,1H:OH 1);1,71(s,3H:CH3);1,99和2,47(2mts,1H单峰:CH2 6);2,15(s,3H:CH3);2,32和2,93(2 dd,J=15和9和J=15和6,5,1H单峰:CH2 14);2,89(d,J=5,1H:H 3);3,45和3,51(2s,3H单峰:OCH3);4,10(dd,J=10,5和7,1H:H 7);4,17(AB极限J=16,2H:OCOCH2O);4,41(d,J=5,1H:H 2);4,43和4,79(2 d,J=10,1H单峰:CH2 20);4,93(mt,1H:H 13);5,10(d宽,J=10,1H:H 5);6,51(s,1H:H 10).
实施例2
向18mg 3-叔丁氧羰基氨基-2-羟基-3-苯基-(2R,3S)-丙酸2α-苯甲酸基-4α-乙氧基-5β,20-环氧-1β,10β-二羟基-9-氧-7β-三氟甲磺酰氧-11-紫杉烯-13α-酯与233μl乙腈和23μl四氢呋喃形成的溶液中依次加入15mg粉状4A分子筛和27mgNaCl。在约75℃将反应混合物搅拌3小时,随后在约20℃,加入1 5cm3CH2Cl2和15cm3NaCl饱和水溶液。倾析有机相,用NaCl饱和水溶液10cm3洗涤2次,随后用MgSO4干燥,过滤并在40℃减压(2.7KPa)浓缩至干。得到22mg产物,用制备色谱法(硅胶片厚度为0.25mm)提纯(洗提剂:CH2Cl2-CH3OH:95/5体积),得到10mg白色烤蛋白状3-叔丁氧羰基氨基-2-羟基-3-苯基-(2R,4S)丙酸2α-苯甲酸基-5β,20-环氧-1β,10β-二羟基-7β,8-亚甲基-19-降-9-氧-4α-乙氧基-11-紫杉烯-13α-酯,其特征在于:-质子核磁共振谱(400Mhz;CDCl3;δppm;偶合常数J Hz):1,21(s,3H:CH3);1,28(s,3H:CH3);1,37(s,9H:C(CH3)3);1,35(mt,1H:H7);1,47(t,J=7,3H:CH3 C2H5 4);1,72(s,1H:OH 1);1,84和2,32(t和dd,J=6和J=10和6,1H单峰:CH2 19);1,89(s,3H:CH3);2,03 et 2,22(dt和d宽,J=16和4和J=16,1H单峰:CH2 6);2,20和2,90(dd和dd宽,J=16和9,1H单峰:CH2 14);3,22(mf,1H:OH 2′);3,47 和3,68(2mts,1H单峰CH2C2H5 4);3,65(d,J=7,1H:H 3);4,02 和4,39(2 d,J=9,1H单峰:CH220);4,26(s宽,1H:OH 10);4,61(mt,1H:H 2′);4,87(mt,1H:H5);4,95(s宽,1H:H 10);5,33(d宽J=10,1H:H 3′);5,42(d,J=10,1H:CONH);5,67(d,J=7,1H:H 2);6,28(t宽,J=9,1H:H en 13);7,30~7,45(mt,5H:H芳香3′);7,49(t,J=7,5,2H:OCOC6H5H间位);7,60(t,J=7,5,1H:OCOC6H5H对位);8,11(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备3-叔丁氧羰基氨基-2-羟基-3-苯基-(2R,3S)-丙酸2α-苯甲酰氧-5β,20-环氧-1β,10β-二羟基-9-氧-4α-乙氧基-7β-三氟甲磺酰氧-11-紫杉烯-13α-酯:
将66mg 3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸2α-苯甲酰氧-5β,20-环氧-1β,10β-二羟基-9-氧-4α-乙氧基-7β-三氟甲磺酸基-11-紫杉烯-13α-酯在1.5ml0.1N乙醇盐酸溶液中形成的溶液在约0℃下搅拌19小时。在20℃减压(2.7KPa)浓缩至干。得到82mg产物,在厚度为0.25mm的硅胶片上进行制备色谱提纯(洗提剂:CH2Cl2-甲醇:95-5体积)。得到20mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(600MHz;CDCl3;δppm;偶合常数J Hz):1,13(s,3H:CH3);1,25(s,3H:CH3);1,40(s,9H:C(CH3)3);1,47(t,J=7,3H:CH3 C2H5 4);1,58(s,1H:OH 1);1,90和2,25(mt和dd,J=16和9,1H单峰:CH2 14);1,92(s,3H:CH3);1,94(s,3H:CH3);2,40和2,70(2 mts,1H单峰 CH2 6);3,18(s宽,1H:OH 2′);3,43(d,J=6,5,1H:H 3);3,75和3,82(2mts,1H单峰:CH2 C2H5 4);4,05(s宽1H:OH 10);4,28和4,46(2 d,J=9,1H单峰:CH2 20);4,63(mt,1H:H 2′);4,92(dd,J=11和7,1H:H 7);5,03(dd,J=10和2,1H:H5);5,32(mt,1H:H 3′);5,33(s宽,1H:H 10);5,45(d,J=10,1H:CONH);5,65(d,J=6,5,1H:H en 2);6,20(t宽,J=9,1H:H 13);7,30~7,55(mt,5H:H芳香3′);7,49(t,J=7,5,2H:OCOC6H5H间位);7,61(t,J=7,5,1H:OCOC6H5H对位);8,02(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸2α-苯甲酰氧-5β,20-环氧-1β,10β-二羟基-9-氧-4α-乙氧基-7β-三氟甲磺酰氧-11-紫杉烯-13α-酯:
在约20℃向由90mg 2α-苯甲酰氧-1β,10β,13α-三羟基-5β,20-环氧-9-氧-4α-乙氧基-7β-三氟甲磺酰氧-11-紫杉烯在4cm3无水乙酸乙酯中形成的溶液中依次加入60mg 3-叔丁氧羰基-2-(4-甲氧苯基)-4-苯基-1,3-噁唑烷-(2R,4S,5R)-5-羧酸,42mg二环己基碳化二亚胺和5mg 4-二甲氨基吡啶。在氩气氛中在约20℃将反应混合物搅拌6小时,加入30cm3乙酸乙酯和20cm3NH4Cl饱和水溶液。倾析有机相,用20cm3水洗2次,随后用MgSO4干燥。过滤,在40℃减压(2.7KPa)浓缩至干。得到的140mg产物在30g硅胶(0.063-0.2mm)柱(直径为1cm)中进行色谱提纯(洗提剂:环己烷-乙酸乙酯70-30体积),得到8cm3馏份。合并仅含目的化合物的馏份并且在40℃减压(2.7KPa)浓缩至干,得110mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(400MHz;CDCl3;δppm;偶合常数J Hz):1,10(s,15H:C(CH3)3-CH3和CH3 C2H5 4);1,19(s,3H:CH3);1,51(s,1H:OH 1);1,64(s,3H:CH3);1,85(s,3H:CH3);de 2,25~2,40和2,66(2mts,1H单峰:CH2 6);2,25~2,40和2,88(mt和dd,J=16和8,1H单峰CH2 14);3,35(d,J=6,5,1H:H 3);3,52和3,62(2mts,1H单峰:CH2 C2H5 4);3,84(s,3H:ArOCH3);4,01(d,J=1,1H:OH10);4,20和4,34(2d,J=9,1H单峰CH2 20);4,64(d,J=4,1H:H 2′);4,85(dd,J=11,5和6,5,1H:H 7);4,92(d宽J=10,5,1H:H 5);5,26(d,J=1,1H:H 10);5,55(mf展开,1H:H 3′);5,59(d,J=6,5,1H:H 2);5,91(mt,1H:H 13);6,40(mf展开,1H:H 5′);6,94(d,J=8,5,2H:H邻位OCH3);7,30~7,50(mt,9H:H芳香3′,H间位OCH3和OCOC6H5H);7,63(t,J=7,5,1H:OCOC6H5H对位);7,95(d,J=7,5,2H:OCOC6H5H邻位).
按照下述方法制备2α-苯甲酰氧-1β,10β,13α-三羟基-5β,20-环氧-9-氧-4α-乙氧基-7β-三氟甲磺酰氧-11-紫杉烯:
在约0℃向260mg 2α-苯甲酰氧-5β,20-环氧-9-氧-4α-乙氧基-1β,7β,10β,13α-四羟基-11-紫杉烯于10cm3CH2Cl2和145μl吡啶中形成的溶液中滴加200μl三氟甲磺酸(triflic)酐。在约0℃将溶液搅拌45分钟,随后加入10cm3水和15cm3CH2Cl2。倾析有机相,用10cm3NaHCO3饱和水溶液洗涤2次,随后用MgSO4干燥,过滤并在20℃减压(2.7KPa)浓缩至干。得到的308mg产物用60g硅胶(0.063-0.2mm)柱(直径:1cm)进行色谱提纯(洗提剂:乙酸乙酯-环己烷40-60,体积),得到10cm3馏分,合并仅含所需化合物的馏份并在40℃下减压(2.7KPa)浓缩至干。得到90mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(300MHz;CDCl3;δppm;偶合常数J Hz):1,07(s,3H:CH3);1,12(s,3H:CH3);1,47(t,J=7,3H:CH3C2H54);1,87(s,3H:CH3);2,05(s,1H:OH 1);2,15(s,3H:CH3);2,38和2,75(2mts,1H单峰:CH2 6);2,49和2,65(2dd,J=16和9和J=16和3,5,1H单峰:CH2 14);2,89(d,J=10,1H:OH 13);3,72(d,J=6,5,1H:H 3);3,80~3,95(mt,2H:CH2 C2H5 4);3,97(d,J=1,1H:OH 10);4,30和4,48(2d,J=9,1H单峰:CH2 20);4,57(t宽,J=10,1H:H 13);4,95~5,15(mt,2H:H5和H7);5,42(d,J=1,1H:H 10);5,63(d,J=6,5,1H:H 2);7,48(t,J=7,5,2H:OCOC6H5H间位);7,63(t,J=7,5,1H:OCOC6H5H对位);8,00(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备2α-苯甲酰氧-5β,20-环氧-9-氧-4α-乙氧基-1β,7β,10β,13α-四羟基-11-紫杉烯:
向524mg 2α-苯甲酰氧-7β,10β,13α-三(三乙基甲硅烷氧)-5β,20-环氧-1β-羟基-9-氧-4α-甲氧基-11-紫杉烯于8cm3CH2Cl2中形成的溶液中于约20℃加入10cm3配合物三乙胺-氢氟酸。在约20℃将反应混合物搅拌7小时,随后加入100cm3CH2Cl2和200cm3NaHCO3饱和水溶液。倾析有机相,用50cm3NaCl饱和水溶液洗涤2次,随后用MgSO4干燥,过滤并在40℃减压(2.7KPa)浓缩至干。得到260mg白色烤蛋白状目的产物,其物理特征在于:
-质子核磁共振谱(400MHz;CDCl3;δppm;偶合常数
J en Hz):1,06(s,3H:CH3);1,12(s,3H:CH3);1,46(t,J=7,3H:CH3C2H5 4);1,72(s,3H:CH3);1,99和2,50(2mts,1H单峰:CH2 6);2,04(s,1H:OH 1);2,10(s,3H:CH3);2,45~2,55(mt,1H:OH 7);2,50和2,65(mt和dd,J=16和3,5,1H单峰:CH2 14);3,06(d,J=11,1H:OH 13);3,70(d,J=6,5,1H:H 3);3,84(mt,1H:H 7);3,89和3,96(2mts,1H单峰:CH2 C2H5 4);4,15(s宽 1H:OH 10);4,31和4,44(2d,J=9Hz,1H单峰:CH2 20);4,54(t宽J=10,1H:H 13);4,93(dd,J=10和3,5,1H:H 5);5,28(s,1H:H 10);5,63(d,J=6,5,1H:H 2);7,48(t,J=7,5,2H:OCOC6H5H间位);7,61(t,J=7,5,1H:OCOC6H5H对位);8,02(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备2α-苯甲酰氧-1β-羟基-7β,10β,13α-三(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-4α-乙氧基-11-紫杉烯:
1)向253mg 1β,2α-碳酸酯-7β,10β,13α-三(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-4α-乙氧基-11-紫杉烯于13cm3无水四氢呋喃中形成的溶液中加入320μl1M苯基锂于四氢呋喃中形成的约-78℃溶液。在约-78℃搅拌1.5小时,随后加入10cm3NH4Cl饱和水溶液。在约20℃,加入10cm3水和50cm3乙酸乙酯。倾析有机相,用20cm3NaCl饱和水溶液洗涤2次,用MgSO4干燥,过滤,在40℃减压(2.7KPa)浓缩至干。得到的500mg产物在直径为3cm的50g硅胶(0.063-0.2mm)柱上进行色谱提纯(洗提液:乙酸乙酯-环己烷:15-85,体积),得到10cm3馏分,合并仅含目的产物的馏分,于40℃减压(2.7KPa)浓缩至干,得到260mg白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(400 MHz;CDCl3;δppm;偶合常数J Hz):0,55~0,75(mt,18H:CH2 C2H5);0,90~1,10(mt,27H:CH3C2H5);1,15(s,3H:CH3);1,22(s,3H:CH3);1,38(t,J=7,3H:CH3 C2H54);1.50(s,1H:OH 1);1,65(s,3H:CH3);2,00和2,39(2mts,1H单峰:CH26);2,02(s,3H:CH3);2,05和2,85(2dd,J=16和9和J=16和8,5,1H 单峰:CH2 14);3,43(d,J=6,5,1H:H3);3,44和3,90(2mts,1H单峰:CH2 C2H5 4);3,91(mt,1H:H 7);4,20和4,30(2d,J=9,1H单峰:CH2 20);4,93(dd,J=10和3,5,1H:H 5);4,97(t宽,J=9,1H:H 13);5,17(s,1H:H 10);5,60(d,J=6,5,1 H:H 2);7,45(t,J=7,5,2H:OCOC6H5H间位);7,57(t,J=7,5,1H:OCOC6H5H对位;8,06(d,J=7,5,2H:OCOC6H5H邻位).
按照下列方式制备1β,2α-碳酸酯-7β,10β,13α-三(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-4α-乙氧基-11-紫杉烯:
在约20℃和氢气氛下向353mg 1β,2α-碳酸酯-7β,10β,13α-三(三乙基甲硅烷氧)-5β,20-环氧-4α-羟基-9-氧-11-紫杉烯在2.1cm3二甲基甲酰胺中形成的溶液中加入0.3g 4A分子筛、4.2cm3乙基碘和68mg 80%氢化钠。在约20℃搅拌1小时后,加入10cm3NH4Cl饱和水溶液和30cm3CH2Cl2,倾析有机相,用10cm3NaCl饱和水溶液洗涤2次,随后用MgSO4干燥,过滤并在40℃减压(2.7KPa)浓缩至干。得到的500mg产物在直径为1cm的25g硅胶(0.063-2.2mm)柱中进行色谱提纯(洗提液:乙酸乙酯-环己烷:10-90,体积),得到馏分10cm3。合并仅含目的产物的馏分并且在40℃减压(2.7KPa)浓缩至干,得到253mg白色烤蛋白状目的化合物。其物理特征在于:-质子核磁共振谱(400MHz,;CDCl3;δppm;偶合常数
J Hz):0,55~0,75(mt,18H:CH2 C2H5);0,90~1,10(mt,27H:CH3 C2H5);1,17(s,3H:CH3);1,25(s,3H:CH3);1,25(t,J=7,3H:CH3
C2H5 4);1,68(s,3H:CH3);1,98和2,47(2mts,1H单峰:CH2 6);1,98(s,3H:CH);2,26和3,07(2 dd,J=16和9和J=16和7,1H单峰CH2 14);2,87(d,J=5 Hz,1H:H 3);3,71和3,82(2mts,1H单峰:CH2 C2H5 4);4,05(dd,J=10和7,1H:H 7);4,39(d,J=5,1H:H 2);4,45和4,77(2d,J=9,1H单峰n:CH2 20);4,97(mt,1 H:H 13);5,03(d宽,J=10,1H:H 5);5,15(s,1H:H 10).
按照下列方式制备1β,2α-碳酸酯-7β,10β,13α-三(三乙基甲硅烷氧基)-5β,20-环氧-4α-羟基-9-氧-11-紫杉烯:
向98mg 1β,2α-碳酸酯-4α,10β-二羟基-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-11紫杉烯在1cm3二甲基甲酰胺中形成的溶液中在氩气氛和约20℃下加入51mg咪唑和50μl三乙基氯硅烷。在约20℃将反应混合物搅拌72小时,随后加入10cm3水和20cm3乙酸乙酯。倾析有机相,用NaCl饱和水溶液10cm3洗涤2次,随后用MgSO4干燥,过滤并在40℃减压(0.27KPa)浓缩至干。所得到的190mg残余物通过2mm厚的薄层制备色谱提纯(洗提液:乙酸乙酯-环己烷:25-75,体积),得到58mg白色烤蛋白状目的化合物,其特征在于:-质子核磁共振谱(400MHz;CDCl3;δppm;偶合常数J Hz):0,50~0,70和0,74(2 mts,12H和6H:CH2 C2H5);0,90~1,10(mt,27H:CH3 C2H5);1,14(s,3H:CH3);1,19(s,3H:CH3);1,63(s,3H:CH3);1,98和2,50(2mts,1H单峰CH2 6);1,98(s,3H:CH3);2,55和2,67(2 dd,J=16和9和J=16和3,5,1H单峰:CH2 14);3,00(s,1H:OH 4);3,11(d,J=5,1H:H 3);4,14(dd,J=10和7,1H:H7);4,33(d,J=5,1H:H 2);4,54(AB极限,J=9,2H:CH2 20);4,73(d宽,J=9,1H:H 13);4,77(d宽,J=10,1H:H 5);5,23(s,1H:H 10).
按照下列方式制备1β,2α-碳酸酯-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-4α,10β-二羟基-9-氧-11-紫杉烯:
向108mg1β,2α-碳酸酯-4α-羟基-7β,13α-二(三乙基甲硅烷氧基)-5β,20-环氧-10β-甲氧乙酸基-9-氧-11-紫杉烯在3.5cm3甲醇中形成的溶液中在约20℃和氩气氛中滴加入0.3g 4A分子筛和470mg碘化锌。在此温度下将反应混合物搅拌72小时,随后加入10cm3水和20cm3乙酸乙酯。倾析有机相,用NaCl饱和水溶液10cm3洗涤2次,用MgSO4干燥,过滤并在40℃减压(2.7KPa)浓缩至干。得到的90mg产物在2mm厚薄层上进行制备色谱提纯(洗提剂:乙酸乙酯-环己烷,25-75,体积),得到56mg目的化合物,其特征如下: -质子核磁共振谱(400MHz;CDCl3;δppm;偶合常数J Hz):0,54和0,74(2mts,6H单峰:CH2 C2H5);0,91和1,03(2t,J=7,5Hz,9H单峰:CH3 C2H5);1,12(s,3H:CH3);1,20(s,3H:CH3);1,72(s,3H:CH3);1,98和2,46(2mts,1H单峰:CH2 6);2,04(s,3H:CH3);2,55和2,67(2 dd,J=16和9和J=16和3,5,1H单峰:CH2 14);3,00(s,1H:OH 4):3,14(d,J=5,1H:H 3);4,07(dd,J=10和7,1H:H 7);4,19(d,J=2,1H:OH 10);4,33(d,J=5,1H:H 2);4,54(AB极限,J=10,2H:CH2 20);4,76(d,宽,J=9,1H:H 13);4,82(d宽,J=10,1H:H 5);5,18(d,J=2,1H:H 10).
2)向200mg 2α-苯甲酸基-1β,4α-二羟基-7β,10β13α-三(三乙基甲硅烷氧基)-5β,20-环氧-9-氧-11紫杉烯在6cm3二甲基甲酰胺中形成的溶液中在氩气氛和约20℃条件下加入0.3g分子筛4A、1cm3乙基碘和34mg 50%氢化钠。在约20℃将反应混合物搅拌1小时,加入10cm3NH4Cl饱和水溶液和30cm3乙酸乙酯,倾析有机相,用10cm3NaCl饱和水溶液洗涤2次,随后用MgSO4干燥,过滤并在40℃减压(2.7KPa)浓缩至干。得到的320mg产物在直径为1cm的100g硅胶(0.063-2.2mm)柱中进行色谱提纯(洗提液:乙酸乙酯-环己烷:10-90,体积),得到馏分10cm3。合并仅含目的产物的馏分并且在40℃减压(2.7KPa)浓缩至干,得到38mg白色烤蛋白状2α-苯甲酸基-4α-乙氧基-5β,20-环氧-1β-羟基-9-氧-7β,10β,13α-三(三乙基甲硅烷氧基)-11-紫杉烯,其物理特征与上述得到的产物相同。
按照下列方式制备2α-苯甲酸基-1β,4α-二羟基-5β,20-环氧-9-氧-7β,10β,13α-三(三乙基硅烷氧基)-11-紫杉烯:
向4.2g按照D.G.Kingston等人在Tetrahedron Letters 356839(1994)中所述方法制备的2α-苯甲酸基-5β、20-环氧-9-氧-1β,4α,10β,13α-四羟基-7β-三乙基甲硅烷氧基-11-紫杉烯与50cm3二甲基甲酰胺形成的溶液中于约20℃和氩气氛下加入4.6g咪唑和2.35g三乙基氯硅烷。在约20℃搅拌72小时,加入30cm3水和100cm3乙酸乙酯。倾析有机相,用30cm3NaCl饱和水溶液洗涤2次,用MgSO4干燥,过滤并在40℃减压(2.7KPa)浓缩至干。得到的12g产物在直径为3cm的100g硅胶(0.063-0.2mm)柱中进行色谱提纯(洗提液:乙酸乙酯-环己烷:10-90,体积)得到馏分20cm3。合并仅含目的产物的馏分并且在40℃减压(2.7KPa)浓缩至干。得到3.6g白色烤蛋白状目的化合物,其物理特征在于:-质子核磁共振谱(300MHz;CDCl3;δppm;偶合常数J Hz):0,57和0,60-0,85(2mts,6H和12H:CH2 C2H5);0,90~1,10(mt,30H:CH3在C2H5和CH3);1,21(s,3H:CH3);1,53(s,3H:CH3);1,63(s,1H:OH 1);1,96(s,3H:CH3);1,97和2,45(2mts,1H单峰:CH2 6);2,32和2,60(2dd,J=16和9和J=16和2,5,1H单峰:CH2 14);3.61(d,J=6,1H:H 3);3,80(s宽,1H:OH 4);4,05(dd,J=11,5和6,1H:H 7);4,23和4,27(AB极限J=9,2H:CH2 20);4,64(d宽,J=9,1 H:H 13);4,71(dd,J=10和4,1H:H 5);5,25(s,1H:H10);5,54(d,J=6,1H:H 2);7,42(t,J=7,5,2H:OCOC6H5H间位);7,55(t,J=7,5,1H:OCOC6H5H对位);8,11(d,J=7,5,2H:OCOC6H5H邻位).
其中Z代表通式(II)所示基团的新型化合物I具备明显的抑制不正常细胞增殖的活性并且能够对与不正常细胞增殖相关的病症患者产生治疗作用。这些病症包括不同组织和/或器官的恶性细胞或非恶性细胞的不正常细胞增殖,这些器官和/或组织包括,但不限于肌肉组织、骨骼或结缔组织、皮肤、脑、肺、性器官、淋巴系统或肾、乳房细胞或血细胞、肝、消化器官、肾上腺、胰腺和甲状腺。这些病症还包括固体肿瘤、牛皮癣、卵巢癌、乳腺癌、脑癌、前列腺癌、肠癌、胃癌、肾癌或睾丸癌、Kaposi肉瘤、胆管癌、绒毛膜癌、神经母细胞癌、Wilms肿瘤、Hodgkin病、黑素瘤、多发性骨髓瘤、慢性淋巴性白血病、急性或慢性颗粒细胞淋巴瘤。本发明的新型化合物特别适用于治疗卵巢癌。本发明化合物可被用于防治或延缓这些病症的出现或复发或用于治疗这些疾病。
本发明的化合物可以依据适用于所选用的给药途径的不同形式被施用于患者,这些给药途径以非肠胃方式为佳。非肠胃给药包括静脉内给药、腹膜内给药、肌肉或皮下给药。更优选腹膜内或静脉内给药。
本发明还包括含有至少一种其数量足以适用于人体或兽体治疗的化合物I的药物组合物。该组合物可按照常规方法采用一种或多种药物可接受的助剂、载体或赋形剂来制备。适宜的载体包括稀释剂、无菌含水介质和无毒溶剂。该组合物优选以水溶液或悬浮液、可被注射溶液的形式存在,其中含有乳化剂、着色剂、防腐剂或稳定剂。
可以依据产物的溶解性和化学性质、具体的给药途径和有经验的药剂实践选择助剂或赋形剂。
对于非肠胃给药来说,可以使用含水或不含水无菌溶液或悬浮液。为了制备非水溶液或悬浮液,可以使用天然植物油如橄榄油、芝麻油或石蜡油或可注射有机酯如油酸乙酯。无菌水溶液可以由药物可接受的盐的水溶液构成。这些水溶液适合于在宜于通过例如足量NaCl或葡萄糖调节其PH值和实现等渗性的条件下进行静脉内注射。可以通过加热或其它任何不改变组成的方式进行灭菌处理。
当然,所有进入本发明组合物的化合物都应该是纯态的或者对其用量来说是无毒的。
该组合物可以含有至少0.01%治疗活性化合物。组合物中活性化合物的数量符合剂量学标准。优选地,该组合物的制备方式导致非肠胃给药单位剂量含约0.01-1000mg活性化合物。
治疗过程可以与包括抗致瘤药疗法、单克隆抗体疗法、免疫治疗或放射治疗在内的其它疗法或生物响应改性疗法共同进行。响应改性剂包括,但不限于淋巴细胞活素和细胞因子如白介素、干扰素(α、β或δ)和TNF。其它在治疗由于细胞不正常增殖造成的疾病过程中适用的化学治疗剂包括,但不限于烷基化剂如氮芥类例如氮芥、环磷酰胺、美法仑和苯丁酸氮芥,磺酸烷基酯如白消安,亚硝替脲如卡莫司汀、洛莫司汀、司莫司汀和链佐星,三氮烯如达卡巴嗪,抗代谢物如叶酸类似物例如甲氨蝶呤,嘧啶类似物如氟尿嘧啶和阿糖胞苷,嘌呤的类似物如巯嘌呤和硫鸟嘌呤,天然化合物如长春花属生物碱如长春碱、长春新碱和Vendesine,表鬼臼毒素如依托泊甙和替尼泊甙,抗生素如放线菌素D、柔红霉素、阿霉素、博来霉素、普卡霉素和丝裂霉素C,酶如门冬酰胺酶,其它试剂如铂的配合物例如顺铂、被取代尿素例如羟基脲,甲肼衍生物如丙卡巴肼,肾上腺皮质抑制剂如米托坦和氨鲁米特,激素与拮抗剂如肾上腺皮质类固醇如泼尼松,黄体制剂如羟孕酮己酸酯、甲氧孕甾酮乙酸酯和甲地孕酮乙酸酯,雌激素如己烯雌酚和乙炔雌二醇;抗雌激素如他莫昔芬,雄激素如丙酸睾酮和氟甲睾酮。
实施本发明方法的剂量可以进行预防治疗或产生最大治疗响应。剂量根据给药形式、所选用的具体化合物和待治疗客体的具体特征确定。一般地,其剂量对于由于不正常细胞增殖导致的疾病具有疗效。本发明化合物可以随时被施用以便产生所需疗效。一些患者可以对较重或较轻剂量迅速产生反应,随后需要少量药剂维持药物作用或完全不需要这种维持作用。一般地,在治疗初期采用小剂量,必要时,剂量越来越大,直至产生最佳疗效为止。对于其它患者而言,根据患者的生理需要每日可以保持1-8次用药、以1-4次为佳,对于某些患者同样可能的是有必要每日只用药1-2次。
人体用药剂量一般为0.01-200mg/kg。对于腹膜内给药,剂量通常为0.1-100mg/kg,以0.5-50mg/kg为佳,以1-10mg/kg为更佳。对于静脉内给药,剂量通常为0.1-50mg/kg,以0.1-5mg/kg为佳,以1-2mg/kg为更佳。 当然,为选择更适宜的剂量,应该考虑给药途径、患者体重、其总体健康状况、其年龄和可以影响疗效的所有因素。
下列实施例描述本发明组合物。
实施例
将40mg实施例1得到的化合物溶于1cm3Emlphor EL 620和1cm3乙醇中,随后用18cm3生理盐水稀释该溶液。
通过导入生理盐水之中将该组合物灌注1小时。
Claims (7)
1.新型紫杉化合物(taxoide)(I)式中:Ra代表氢原子或羟基、C1-4烷氧基、C1-4酰氧基或其烷基部分含1-4个碳原子的烷氧基乙酸基,Rb代表氢原子或者Ra与Rb连同与其结合的碳原子共同形成酮官能团,Z代表氢原子或基团(II):式中:R1代表可被一个或多个相同或不同选自卤原子和C1-4烷基、C1-4烷氧基或三氟甲基的原子或基团取代的苯甲酰基,噻吩甲酰或糠酰,或基团R2-O-CO-,其中R2代表:-C1-8烷基、C2-8链烯基、C3-8炔基、C3-6环烷基、C4-6环烯基、C7-10二环烷基,这些基团可以被一个或多个选自下列取代基的基团取代:卤原子和羟基、C1-4烷氧基、其中每一烷基部分均含1-4个碳原子的二烷基胺基、哌啶子基、吗啉代、哌嗪-1-基(在4-位可以被C1-4烷基或其中烷基部分含1-4个碳原子的苯基烷基取代)、C3-6环烷基、C4-6环烯基、苯基(可以被一个或多个选自卤原子和C1-4烷基或C1-4烷氧基的原子或基团取代)、氰基、羧基或其中烷基部分含1-4个碳原子的烷氧羰基,-可以被一个或多个选自下列原子或基团的取代基取代的苯基或α-或β-萘基:卤原子和C1-4烷基或C1-4烷氧基或优选自呋喃基与噻吩基的5员芳族杂环基,-或可被一个或多个C1-4烷基取代的C4-6饱和杂环基,R3代表直链或支链C1-8烷基,直链或支链C2-8链烯基,直链或支链C2-8炔基,C3-6环烷基,可被一个或多个选自下列原子或基团的取代基取代的苯基或α-或β-萘基:卤原子、烷基、链烯基、炔基、芳基、芳烷基、烷氧基、烷硫基、芳氧基、芳硫基、羟基、羟烷基、巯基、甲酰基、酰基、酰氨基、芳酰氨基、烷氧羰基氨基、氨基、烷基氨基、二烷基氨基、羧基、烷氧羰基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、氰基、硝基与三氟甲基,或含一个或多个选自氮、氧或硫的相同或不同杂原子的可被一个或多个相同或不同选自下列基团的取代基取代的5员芳族杂环:卤原子和烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧羰基氨基、酰基、芳基羰基、氰基、羧基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰或烷氧羰基,条件是在苯基、α-或β-萘基与芳族杂环基的取代基中,烷基与其它基团的烷基部分含1-4个碳原子并且链烯基与炔基含2-8个碳原子以及芳基为苯基或α-或β-萘基,R4代表-直链或支链C1-8烷基,直链或支链C2-8链烯基,直链或支链C2-8炔基,C3-6环烷基,C4-6环烯基或C7-11二环烷基,这些基团可以被一个或多个选自下列取代基的基团取代:卤原子和羟基、C1-4烷氧基、其中每一个烷基部分均含1-4个碳原子的二烷基氨基、哌啶子基、吗啉代、哌嗪-1-基(在4-位可被C1-4烷基或其烷基部分含1-4个碳原子的苯基烷基取代)、C3-6环烷基、C4-6环烯基、可被取代的苯基、氰基、羧基或其烷基部分含1-4个碳原子的烷氧羰基,-或者可被一个或多个选自下列原子或基团的取代基取代的芳基:卤原子和烷基、链烯基、炔基、芳基、芳烷基、烷氧基、烷硫基、芳氧基、芳硫基、羟基、羟烷基、巯基、甲酰基、酰基、酰氨基、芳酰氨基、烷氧羰基氨基、氨基、烷基氨基、二烷基氨基、羧基、烷氧羰基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、氰基、硝基、叠氮基、三氟甲基或三氟甲氧基,或可被一个或多个C1-4烷基取代的4-6员饱和或不饱和杂环基,R5代表-直链或支链C1-8烷基,直链或支链C2-8链烯基,直链或支链C2-8炔基,C3-6环烷基,C4-6环烯基或C7-11二环烷基,这些基团可以被一个或多个选自下列取代基的基团取代:卤原子和羟基、C1-4烷氧基、其中每一个烷基部分均含1-4个碳原子的二烷基氨基、哌啶子基、吗啉代、哌嗪-1-基(在4-位可被C1-4烷基或其烷基部分含1-4个碳原子的苯基烷基取代)、C3-6环烷基、C4-6环烯基、可被取代的苯基、氰基、羧基或其烷基部分含1-4个碳原子的烷氧羰基,条件是环烷基、环烯基或二环烷基可以被一个或多个C1-4烷基取代。
2.按照权利要求1的新型紫杉化合物,其中Ra代表羟基、C1-4烷氧基、C1-4酰氧基或其中烷基部分含1-4个碳原子的烷氧基乙酸基,Rb代表氢原子;Z代表氢原子或通式II所示基团,其中R1代表苯甲酰基或其中R2代表叔丁基的基团R2-O-CO-,R3代表C1-6烷基、C2-6链烯基、C3-6环烷基、可被一个或多个相同或不同选自下列原子或基团的取代基取代的苯基:卤原子(氟、氯)和烷基、烷氧基、二烷基氨基、酰氨基、烷氧羰基氨基或三氟甲基或呋喃-2-基或呋喃-3-基、噻吩-2或-3-基或噻唑-2,-4或-5-基,R4代表可被一个或多个相同或不同选自下列原子或基团的取代基取代的苯基:卤原子和烷基、烷氧基、氨基、烷基氨基、二烷基氨基、酰基氨基、烷氧羰基氨基、叠氮基、三氟甲基和三氟甲氧基,或噻吩-2或-3-基或呋喃-2或-3-基,R5代表可被取代的C1-4烷基。
3.按照权利要求1的新型紫杉化合物,其中Ra代表氢原子或羟基或乙酸基或甲氧乙酸基,Rb代表氢原子,Z代表氢原子或通式(II)所示基团,其中R1代表苯甲酰基或其中R2代表叔丁基的基团R2-O-CO-,R3代表异丁基、异丁烯基、丁烯基、环己基、苯基、呋喃-2-基、呋喃-3-基、噻吩-2-基、噻吩-3-基、噻唑-2-基、噻唑-4-基或噻唑-5-基,R4代表可被一个卤原子取代的苯基,R5代表C1-4烷基。
4.权利要求1-3中任一项的化合物的制备方法,其特征在于可以通过碱金属卤化物或碱金属叠氮化物或季铵盐或碱金属的磷酸盐对通式(III)所示化合物产生作用以便得到通式(V)所示的化合物随后如果需要用氢原子替代Ra带有的或R7和/或R6与R7表示的保护基来制备:式中Z1代表氢原子或式II所示其中R1与R3如上定义的基团或下式所示基团式中R1与R3如上限定,或R6代表氢原子,R7代表羟基官有团的保护基,或R6与R7共同形成5或6员饱和杂环,R4、R5如上限定,Ra代表氢原子或烷氧基、酰氧基、烷氧乙酸基或被保护羟基,优选2,2,2-三氯乙氧羰基氧,Rb代表氢原子,或Ra与Rb以及与它们连结的碳原子共同形成酮官能团,式中Z1、R4、R5、Ra与Rb如上限定。
5.权利要求1-3中任一项的化合物的制备方法,其中R4与R5如权利要求1-3限定,Ra和Rb分别为氢原子,其特征在于权利要求1-3的其中Ra为羟基、酰氧基或烷氧乙酸基的化合物通过电解法得到还原。
6.权利要求1-3中任一项的化合物的制备方法,其中R4与R5如权利要求1-3限定,Ra和Rb连同与其结合的碳原子共同形成酮官能团,其特征在于权利要求1-3的其中Ra为羟基、并且Rb为氢原子的化合物被氧化。
7.药物组合物,其特征在于含有至少一种权利要求1-3的其中Z代表通式II所示基团、与一种或多种惰性或药理活性药物可接受化合物结合的化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/12795 | 1994-10-26 | ||
FR9412795A FR2726272B1 (fr) | 1994-10-26 | 1994-10-26 | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1166170A true CN1166170A (zh) | 1997-11-26 |
Family
ID=9468223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95195914A Pending CN1166170A (zh) | 1994-10-26 | 1995-10-23 | 新型紫杉化合物、其制备方法及其药物组合物 |
Country Status (26)
Country | Link |
---|---|
US (1) | US5840931A (zh) |
EP (1) | EP0788492B1 (zh) |
JP (1) | JPH10508015A (zh) |
KR (1) | KR970707113A (zh) |
CN (1) | CN1166170A (zh) |
AT (1) | ATE178326T1 (zh) |
AU (1) | AU704719B2 (zh) |
BG (1) | BG62697B1 (zh) |
BR (1) | BR9510235A (zh) |
CA (1) | CA2202682A1 (zh) |
CZ (1) | CZ287649B6 (zh) |
DE (1) | DE69508781T2 (zh) |
DK (1) | DK0788492T3 (zh) |
ES (1) | ES2131864T3 (zh) |
FR (1) | FR2726272B1 (zh) |
GR (1) | GR3029838T3 (zh) |
HU (1) | HUT77930A (zh) |
NO (1) | NO971765L (zh) |
NZ (1) | NZ294880A (zh) |
OA (1) | OA10417A (zh) |
PL (1) | PL319834A1 (zh) |
RO (1) | RO115876B1 (zh) |
RU (1) | RU2153496C2 (zh) |
SK (1) | SK281556B6 (zh) |
WO (1) | WO1996013494A1 (zh) |
ZA (1) | ZA958997B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5973160A (en) | 1992-12-23 | 1999-10-26 | Poss; Michael A. | Methods for the preparation of novel sidechain-bearing taxanes |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6433187B1 (en) | 1998-12-17 | 2002-08-13 | Tularik Inc. | Certain polycyclic compounds useful as tubulin-binding agents |
US6916942B2 (en) * | 2000-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Process for the preparation of C-4 carbonate taxanes |
US6750246B1 (en) * | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
MXPA03002494A (es) * | 2000-09-22 | 2004-05-24 | Bristol Myers Squibb Co | Metodo para reducir toxicidad de quimio terapias combinadas. |
US6956124B2 (en) | 2003-04-14 | 2005-10-18 | Aventis Pharma S.A. | Process for the preparation of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene |
FR2853651B1 (fr) * | 2003-04-14 | 2005-05-20 | Aventis Pharma Sa | Procede de preparation du 4,10 beta-diacetoxy-2 alpha- benzoyloxy-5 beta, 20-epoxy-1, 13 alpha-dihydroxy-9-oxo-19- norcyclopropa[g]tax-11-ene |
WO2004103344A1 (en) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399726A (en) * | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
FR2698871B1 (fr) * | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
MX9307777A (es) * | 1992-12-15 | 1994-07-29 | Upjohn Co | 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. |
FR2710642B1 (fr) * | 1993-09-29 | 1995-11-17 | Rhone Poulenc Rorer Sa | Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
-
1994
- 1994-10-26 FR FR9412795A patent/FR2726272B1/fr not_active Expired - Fee Related
-
1995
- 1995-10-23 CZ CZ19971257A patent/CZ287649B6/cs not_active IP Right Cessation
- 1995-10-23 PL PL95319834A patent/PL319834A1/xx unknown
- 1995-10-23 SK SK519-97A patent/SK281556B6/sk unknown
- 1995-10-23 HU HU9800793A patent/HUT77930A/hu unknown
- 1995-10-23 KR KR1019970702730A patent/KR970707113A/ko not_active Application Discontinuation
- 1995-10-23 WO PCT/FR1995/001393 patent/WO1996013494A1/fr not_active Application Discontinuation
- 1995-10-23 DK DK95935998T patent/DK0788492T3/da active
- 1995-10-23 JP JP8514352A patent/JPH10508015A/ja active Pending
- 1995-10-23 CN CN95195914A patent/CN1166170A/zh active Pending
- 1995-10-23 US US08/817,742 patent/US5840931A/en not_active Expired - Fee Related
- 1995-10-23 BR BR9510235A patent/BR9510235A/pt not_active Application Discontinuation
- 1995-10-23 AT AT95935998T patent/ATE178326T1/de not_active IP Right Cessation
- 1995-10-23 NZ NZ294880A patent/NZ294880A/xx unknown
- 1995-10-23 RU RU97108134/04A patent/RU2153496C2/ru active
- 1995-10-23 CA CA002202682A patent/CA2202682A1/fr not_active Abandoned
- 1995-10-23 ES ES95935998T patent/ES2131864T3/es not_active Expired - Lifetime
- 1995-10-23 AU AU38091/95A patent/AU704719B2/en not_active Ceased
- 1995-10-23 RO RO97-00800A patent/RO115876B1/ro unknown
- 1995-10-23 EP EP95935998A patent/EP0788492B1/fr not_active Expired - Lifetime
- 1995-10-23 DE DE69508781T patent/DE69508781T2/de not_active Expired - Fee Related
- 1995-10-24 ZA ZA958997A patent/ZA958997B/xx unknown
-
1997
- 1997-04-17 NO NO971765A patent/NO971765L/no not_active Application Discontinuation
- 1997-04-25 OA OA60995A patent/OA10417A/fr unknown
- 1997-04-25 BG BG101442A patent/BG62697B1/bg unknown
-
1999
- 1999-04-01 GR GR990400221T patent/GR3029838T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996013494A1 (fr) | 1996-05-09 |
RU2153496C2 (ru) | 2000-07-27 |
BG62697B1 (bg) | 2000-05-31 |
GR3029838T3 (en) | 1999-07-30 |
BG101442A (en) | 1998-03-31 |
ZA958997B (en) | 1996-05-15 |
NO971765D0 (no) | 1997-04-17 |
NO971765L (no) | 1997-04-17 |
AU704719B2 (en) | 1999-04-29 |
DK0788492T3 (da) | 1999-10-11 |
DE69508781T2 (de) | 1999-09-02 |
MX9702742A (es) | 1997-09-30 |
DE69508781D1 (de) | 1999-05-06 |
EP0788492A1 (fr) | 1997-08-13 |
US5840931A (en) | 1998-11-24 |
SK281556B6 (sk) | 2001-05-10 |
ES2131864T3 (es) | 1999-08-01 |
ATE178326T1 (de) | 1999-04-15 |
FR2726272B1 (fr) | 1996-12-06 |
FR2726272A1 (fr) | 1996-05-03 |
CZ125797A3 (en) | 1997-08-13 |
HUT77930A (hu) | 1998-11-30 |
RO115876B1 (ro) | 2000-07-28 |
AU3809195A (en) | 1996-05-23 |
KR970707113A (ko) | 1997-12-01 |
CZ287649B6 (en) | 2001-01-17 |
NZ294880A (en) | 1999-02-25 |
PL319834A1 (en) | 1997-09-01 |
SK51997A3 (en) | 1997-10-08 |
CA2202682A1 (fr) | 1996-05-09 |
OA10417A (fr) | 2001-12-05 |
JPH10508015A (ja) | 1998-08-04 |
BR9510235A (pt) | 1997-11-04 |
EP0788492B1 (fr) | 1999-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1152870C (zh) | 新的紫杉化合物,其制备方法及其药物组合物 | |
CN1055467C (zh) | 紫杉类化合物、其制备以及含有它们的药物组合物 | |
CN1103766C (zh) | 新的紫杉化合物、其制备方法及其药物组合物 | |
NZ262137A (en) | 2-hydroxy and 2-acyloxy taxoid derivatives, preparation, intermediates and pharmaceutical compositions thereof | |
CN1166170A (zh) | 新型紫杉化合物、其制备方法及其药物组合物 | |
AU715228B2 (en) | Taxoids, preparation thereof and pharmaceutical compositions containing same | |
CN1073106C (zh) | 新的紫杉化合物,其制备方法及其药物组合物 | |
CN1150423A (zh) | 新型紫杉化合物、其制备方法及其药物组合物 | |
US20010051736A1 (en) | Methods of treating cell lines expressing multidrug resistance P-glycoprotein | |
CN1150422A (zh) | 新的紫杉化合物、其制备方法和药物组合物 | |
FR2742753A1 (fr) | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent | |
MXPA96006227A (en) | Novedous taxoids your preparation and the pharmaceutical compositions that contain them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |